Stifel Nicolaus Reiterates “Buy” Rating for Aerie Pharmaceuticals, Inc. (AERI)

Stifel Nicolaus reiterated their buy rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research note released on Friday, May 26th.

A number of other equities analysts have also commented on AERI. Canaccord Genuity set a $56.00 price objective on Aerie Pharmaceuticals and gave the stock a buy rating in a research note on Saturday, March 11th. Aegis reiterated an in-line rating and issued a $63.00 target price on shares of Aerie Pharmaceuticals in a report on Wednesday, March 8th. Needham & Company LLC reiterated a buy rating and issued a $58.00 target price (up from $52.00) on shares of Aerie Pharmaceuticals in a report on Wednesday, March 8th. Cantor Fitzgerald set a $56.00 price objective on Aerie Pharmaceuticals and gave the company a buy rating in a report on Wednesday, May 24th. Finally, HC Wainwright set a $69.00 price objective on Aerie Pharmaceuticals and gave the company a buy rating in a report on Saturday, April 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $61.00.

Aerie Pharmaceuticals (NASDAQ AERI) traded down 1.75% during midday trading on Friday, reaching $50.50. 549,619 shares of the company were exchanged. Aerie Pharmaceuticals has a one year low of $16.45 and a one year high of $59.50. The firm’s 50-day moving average is $46.66 and its 200-day moving average is $44.03. The firm’s market cap is $1.70 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.76) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by $0.02. On average, equities analysts expect that Aerie Pharmaceuticals will post ($2.59) EPS for the current fiscal year.

WARNING: “Stifel Nicolaus Reiterates “Buy” Rating for Aerie Pharmaceuticals, Inc. (AERI)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/06/20/aerie-pharmaceuticals-inc-aeri-given-buy-rating-at-stifel-nicolaus-updated-updated-updated.html.

In other Aerie Pharmaceuticals news, Director Gerald D. Cagle acquired 2,000 shares of the company’s stock in a transaction on Wednesday, April 19th. The stock was acquired at an average price of $41.70 per share, for a total transaction of $83,400.00. Following the acquisition, the director now owns 10,900 shares in the company, valued at approximately $454,530. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The disclosure for this sale can be found here. Company insiders own 9.36% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Guggenheim Capital LLC boosted its position in Aerie Pharmaceuticals by 4.2% in the fourth quarter. Guggenheim Capital LLC now owns 34,135 shares of the company’s stock worth $1,292,000 after buying an additional 1,384 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in Aerie Pharmaceuticals by 1.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 136,106 shares of the company’s stock worth $6,173,000 after buying an additional 1,388 shares during the last quarter. First Mercantile Trust Co. boosted its position in Aerie Pharmaceuticals by 29.9% in the first quarter. First Mercantile Trust Co. now owns 7,031 shares of the company’s stock worth $319,000 after buying an additional 1,620 shares during the last quarter. HighTower Advisors LLC boosted its position in Aerie Pharmaceuticals by 7.5% in the first quarter. HighTower Advisors LLC now owns 27,426 shares of the company’s stock worth $1,243,000 after buying an additional 1,907 shares during the last quarter. Finally, Federated Investors Inc. PA boosted its position in Aerie Pharmaceuticals by 88.7% in the fourth quarter. Federated Investors Inc. PA now owns 4,447 shares of the company’s stock worth $168,000 after buying an additional 2,090 shares during the last quarter. Institutional investors own 91.75% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply